EGFR and adenocarcinoma: Furthermore, in preclinical models, programmed death 1 (PD-1) antibody blockade improved survival in mice with EGFR-driven adenocarcinoma by enhancing effector T cell function and reducing the levels of tumor-promoting cytokines [12], suggesting that ICI treatment for EGFR-mutated cases may be beneficial.